Changing practice of anticoagulation: Will target-specific anticoagulants replace warfarin?

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 241-253

  Arepally, Gowthami M ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

factor Xa inhibitor; novel anticoagulants; thrombin inhibitor; vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; EDOXABAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULATION; ARTICLE; BLEEDING; BREAST FEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG COST; EMBOLISM; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DISEASE; LIVER DISEASE; PREGNANCY; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; STROKE;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84921367759     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051113-024633     Document Type: Article

References (68)

1. Diener HC, Eikelboom J, Granger CB, HackeW. 2012. The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?. Int. J. Stroke 7:139-41
2. Landefeld CS, Beyth RJ. 1993. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med. 95:315-28
3. AgenoW, Gallus AS, Wittkowsky A, et al. 2012. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e44S-88S
4. Leissinger CA, Blatt PM, HootsWK, Ewenstein B. 2008. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am. J. Hematol. 83:137-43
5. Yeh CH, Fredenburgh JC, Weitz JI. 2012. Oral direct factor Xa inhibitors. Circ. Res. 111:1069-78
6. Nar H. 2012. The role of structural information in the discovery of direct thrombin and factor Xa inhibitors. Trends Pharmacol. Sci. 33:279-88
7. You JJ, Singer DE, Howard PA, et al. 2012. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e531S-75S
8. PatelMR, Mahaffey KW, Garg J, et al. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365:883-91
9. Granger CB, Alexander JH, McMurray JJ, et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365:981-92
10. Giugliano RP, Ruff CT, Braunwald E, et al. 2013. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369:2093-104
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361:1139-51
12. Wallentin L, Yusuf S, Ezekowitz MD, et al. 2010. Efficacy and safety of dabigatran comparedwithwarfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975-83
13. January CT, Wann LS, Alpert JS, et al. 2014. 2014 AHA/ACC/HRS guideline for themanagement of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64:e1-76
14. Falck-Ytter Y, Francis CW, JohansonNA, et al. 2012. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e278S-325S
15. Eriksson BI, Dahl OE, Huo MH, et al. 2011. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb. Haemost. 105:721-29
16. Turpie AG, Lassen MR, Eriksson BI, et al. 2011. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 105:444-53
17. Lassen MR, Gallus A, Raskob GE, et al. 2010. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363:2487-98
18. Lassen MR, Raskob GE, Gallus A, et al. 2010. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807-15
19. Raskob G, CohenAT, ErikssonBI, et al. 2010. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb. Haemost. 104:642-49
20. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. 2011. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365:2167-77
21. Cohen AT, Spiro TE, Buller HR, et al. 2013. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N. Engl. J. Med. 368:513-23
22. Bauersachs R, Berkowitz SD, Brenner B, et al. 2010. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363:2499-510
23. Buller HR, Prins MH, Lensin AW, et al. 2012. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366:1287-97
24. Schulman S, Kearon C, Kakkar AK, et al. 2009. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361:2342-52
25. Agnelli G, Buller HR, Cohen A, et al. 2013. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369:799-808
26. Buller HR, Decousus H, Grosso MA, et al. 2013. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369:1406-15
27. Kearon C, Akl EA, Comerota AJ, et al. 2012. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e419S-94S
28. Schulman S, Kearon C, Kakkar AK, et al. 2013. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 368:709-18
29. Agnelli G, BullerHR, CohenA, et al. 2013. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 368:699-708
30. Mehta SR, Granger CB, Eikelboom JW, et al. 2007. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol. 50:1742-51
31. Olson ST, Swanson R, Raub-Segall E, et al. 2004. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems: comparison with heparin and low-molecular-weight heparin. Thromb. Haemost. 92:929-39
32. Yau JW, Stafford AR, Liao P, et al. 2011. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 118:6667-74
33. Cannegieter SC, Rosendaal FR, Briet E. 1994. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635-41
34. Eikelboom JW, Connolly SJ, Brueckmann M, et al. 2013. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 369:1206-14
35. Hylek EM. 2013. Dabigatran and mechanical heart valves-not as easy as we hoped. N. Engl. J. Med. 369:1264-66
36. Lee AYY, Peterson EA. 2013. Treatment of cancer-Associated thrombosis. Blood 122:2310-17
37. Carrier M, Khorana AA, Zwicker J, et al. 2013. Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J. Thromb. Haemost. 11:1760-65
38. Levine MN, Gu C, Liebman HA, et al. 2012. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost. 10:807-14
39. Malik Q, Crevecoeur LR. 2013. Use of novel oral anticoagulants for treatment of venous thromboembolism (VTE) in patients with malignancy: meta-Analysis of randomized controlled trials. Blood 122:1150 (Abstr.)
40. LymanGH, Khorana AA, KudererNM, et al. 2013. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31:2189-204
41. Farge D, Debourdeau P, Beckers M, et al. 2013. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 11:56-70
42. Linkins L-A, Dans AL, Moores LK, et al. 2012. Treatment and prevention of heparin-induced thrombocytopenia: treatment of HIT: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e495S-e530S
43. Krauel K, HackbarthC, Furll B, Greinacher A. 2012. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 119:1248-55
44. Hirsh J, Heddle N, Kelton JG. 2004. Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Int. Med. 164:361-69
45. Sardar P, Chatterjee S, Herzog E, et al. 2014. Novel oral anticoagulants in patients with renal insufficiency: a meta-Analysis of randomized trials. Can. J. Cardiol. 30:888-97
46. Kedar R, Melamed N, Matlow J, et al. 2013. The transfer of dabigatran and rivaroxaban across a dually perfused isolated human placental cotyledon-implications for therapy in pregnancy. Blood 122:1142 (Abstr.)
47. Rivaroxaban [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2014
48. Dabigatran [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2014
49. Apixaban [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2014
50. Graff J, Harder S. 2013. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin. Pharmacokinet. 52:243-54
51. Martinelli I, Bucciarelli P, Artoni A, et al. 2013. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. Pediatrics 132:e1435-39
52. vanRyn J, Stangier J, Haertter S, et al. 2010. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103:1116-27
53. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. 2012. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb. Res. 129:492-98
54. Douxfils J, Chatelain C, Chatelain B, et al. 2013. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb. Haemost. 110:283-94
55. Reilly PA, Lehr T, Haertter S, et al. 2014. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol. 63:321-28
56. Siegal DM, Garcia DA, Crowther MA. 2014. How I treat target-specific oral anticoagulant-Associated bleeding. Blood 123:1152-58
57. Dickneite G, Hoffman M. 2014. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): What is the evidence?. Thromb. Haemost. 111:189-98
58. DagerWE, Gosselin RC, Roberts AJ. 2013. Reversing dabigatran in life-Threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit. Care Med. 41:e42-e46
59. Maurice-Szamburski A, Graillon T, Bruder N. 2014. Favorable outcome after a subdural hematoma treated with Feiba in a 77-year-old patient treated by rivaroxaban. J. Neurosurg. Anesthesiol. 26:183
60. Harinstein LM, Morgan JW, Russo N. 2013. Treatment of dabigatran-Associated bleeding: case report and review of the literature. J. Pharm. Pract. 26:264-69
61. Schiele F, van Ryn J, Canada K, et al. 2013. A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554-62
62. van Ryn J, Litzenburger T, Gan G, et al. 2013. Evaluation of a specific antidote to dabigatran: in vitro properties, pharmacokinetics and reversal of dabigatran etexilate-induced bleeding in rats. J. Am. Coll. Cardiol. 61:E1825 (Abstr.)
63. Lu G, DeGuzman FR, Hollenbach SJ, et al. 2013. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19:446-51
64. Vandana M, Michael K, Genmin L, et al. 2013. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (prt064445), an antidote for FXa inhibitors. Blood 122:3636 (Abstr.)
65. Harrington AR, Armstrong EP, Nolan PE, Malone DC. 2013. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44:1676-81
66. Kasmeridis C, Apostolakis S, Ehlers L, et al. 2013. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics 31:971-80
67. Coyle D, Coyle K, Cameron C, et al. 2013. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 16:498-506
68. Bauer KA. 2013. Pros and cons of new oral anticoagulants. Hematol. Am. Soc. Hematol. Educ. Program 2013:464-70